Subclinical mastitis in Lacaune sheep: Causative agents, impacts on milk production, milk quality , oxidative profiles and treatment efficacy of ceftiofur.
Animals
Anti-Bacterial Agents
/ pharmacology
Cephalosporins
/ pharmacology
Corynebacterium
/ isolation & purification
Female
Food Quality
Mammary Glands, Animal
/ drug effects
Mastitis
/ drug therapy
Microbial Sensitivity Tests
Milk
/ microbiology
Oxidative Stress
Sheep
Sheep Diseases
/ drug therapy
Staphylococcal Infections
/ drug therapy
Staphylococcus epidermidis
/ isolation & purification
Staphylococcus hyicus
/ isolation & purification
Staphylococcus intermedius
/ isolation & purification
Streptococcal Infections
/ drug therapy
Treatment Outcome
Antimicrobial resistance
Milk sheep
Oxidative stress
Staphylococcus spp
Subclinical mastitis
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
03
07
2019
revised:
06
09
2019
accepted:
06
09
2019
pubmed:
11
9
2019
medline:
31
3
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Mastitis is a major disease affecting dairy sheep. It is caused by microorganisms that generate inflammation of the mammary gland in response to tissue invasion. This syndrome affects the welfare of ewes, as well as the production and quality of the milk, thereby reducing its productive efficiency. Because mastitis causes inflammation process, it also increases the production of free radicals that cause lesions via lipoperoxidation, causing damage to proteins, cells and tissues. One way to minimize the impact of the disease is antimicrobial treatment. Nevertheless, the continuous use of antimicrobials contributes to microbial resistance, in addition to producing residues in the milk and derivatives if not given during the grace period. Therefore, the objective of this study was to evaluate the consequences of subclinical mastitis on ewe health, milk production, milk composition and quality. We also evaluated the susceptibility of the bacteria in vitro using disk diffusion antibiograms. Finally, we performed two-way testing of efficacy of treatment in Lacaune ewes using the same agents. In the first stage of the study, 30 lactating ewes (±90 days) were used, 10 of which were negative on the CMT (California Mastitis Test) used as control group (CG) and 20 sheep with subclinical mastitis diagnosed by CMT (MG). Samples were collected and several analyses were performed on the milk and blood. We found that ewes in the MG had higher lipid peroxidation in serum and milk, as well as lower production, with reduction of the total dry extract in milk. There were 15 isolates of Staphylococcus hyicus, four isolates of each S. epidermidis and S. intermedius, and two isolates of Corynebacterium spp. The primary hematological result was leukocytosis in ewes with mastitis. Based on the antibiogram, we chose ceftiofur for in vivo tests. In this stage, we divided the sheep with subclinical mastitis into two subgroups of 10 ewes each, to receive drug by two routes: intramuscular (IM) and intramammary (IMM). In the IMM group, of the 10 CMT-positive ewes at the beginning of the experiment, seven were already negative by the racket test 120 h after the last application (70% efficacy). In the IM group, of the 10 positive ewes, only four were negative after 120 h of the final application, a low efficacy treatment (40%). We evaluated antimicrobial residues in the milk of treated animals. We found this material within 5 days after treatment in the two forms used; despite the fact that the product's stated withholding period is 3 days. We conclude that ewes with mastitis produce less milk of lower quality. We also conclude that, although ceftiofur is 100% effective in vitro, when used in ewes with mastitis, the efficacy did not exceed 70%, and was more efficient when administered via the intramammary route.
Identifiants
pubmed: 31505264
pii: S0882-4010(19)31197-0
doi: 10.1016/j.micpath.2019.103732
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
ceftiofur
83JL932I1C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103732Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.